Iparomlimab and Tuvoraleimab is named as a drug or biological intervention in 2 clinical trials in our China trial register, none of which are currently recruiting. The lead sponsor is Fudan University. Registered phase: Phase 2. Conditions studied include Acral Melanoma; Mucosal Melanoma; Mesothelioma.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07347444 | Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma (ClinicalTrials.gov ↗) Acral Melanoma, Mucosal Melanoma |
Phase 2 | Not yet open |
| NCT07514793 | Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma (ClinicalTrials.gov ↗) Mesothelioma |
Phase 2 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Acral Melanoma | 1 |
| Mucosal Melanoma | 1 |
| Mesothelioma | 1 |
| Lead sponsor | Trials |
|---|---|
| Fudan University | 2 |
| Register | Iparomlimab and Tuvoraleimab trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Iparomlimab and Tuvoraleimab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Iparomlimab and Tuvoraleimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.